RESUMO
BACKGROUND: Cost of illness studies are important tools to summarise the burden of disease for individuals, the healthcare system and society. The lack of standardised methods for reporting costs for cystic fibrosis (CF) makes it difficult to quantify the total socioeconomic burden. In this study, we aimed to comprehensively report the socioeconomic burden of CF in Canada. METHODS: The total cost of CF in Canada was calculated by triangulating information from three sources (Canadian CF Registry, customised Burden of Disease survey and publicly available information). A prevalence-based, bottom-up, human capital approach was applied, and costs were categorised into four perspectives (ie, healthcare system, individual/caregiver, variable (ie, medicines) and society) and three domains (ie, direct, indirect and intangible). All costs were converted into 2021 Canadian dollars (CAD) and adjusted for inflation. The cost of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies was excluded. RESULTS: The total socioeconomic burden of CF in Canada in 2021 across the four perspectives was $C414 million. Direct costs accounted for two-thirds of the total costs, with medications comprising half of all direct costs. Out-of-pocket costs to individuals and caregivers represented 18.7% of all direct costs. Indirect costs representing absenteeism accounted for one-third of the total cost. CONCLUSION: This comprehensive cost of illness study for CF represents a community-oriented approach describing the socioeconomic burden of living with CF and serves as a benchmark for future studies.
Assuntos
Efeitos Psicossociais da Doença , Fibrose Cística , Custos de Cuidados de Saúde , Humanos , Fibrose Cística/economia , Fibrose Cística/terapia , Fibrose Cística/epidemiologia , Canadá/epidemiologia , Feminino , Masculino , Adulto , Custos de Cuidados de Saúde/estatística & dados numéricos , Adolescente , Adulto Jovem , Criança , Gastos em Saúde/estatística & dados numéricos , Pré-Escolar , Cuidadores/economia , Fatores Socioeconômicos , Lactente , Absenteísmo , Prevalência , Pessoa de Meia-Idade , Sistema de RegistrosRESUMO
BACKGROUND: To examine the burden of exocrine pancreatic insufficiency (EPI), specifically the clinical impact of EPI on patients, their quality of life (QoL) and the cost-effectiveness of existing treatments. METHODS: A systematic literature review was conducted using key search terms for the clinical, economic, and humanistic burden. Databases were searched from 2010 to 2022, with articles screened independently by 2 reviewers at abstract and full-text stage against pre-defined eligibility criteria. RESULTS: Seventy-one publications were identified that reported relevant clinical, humanistic, and economic data. Prevalence and incidence of EPI varied across identified studies; EPI appears to be especially prevalent as a comorbid condition in patients with cystic fibrosis. EPI has a large impact on QoL, with lower QoL scores in patients with EPI compared with those without EPI. The instruments used to assess QoL, however, were inconsistent across studies. Where reported, economic burden studies highlighted that patients with EPI have higher healthcare resource utilization compared with those without, with costs increasing with disease severity. CONCLUSION: This systematic literature review highlights that patients with EPI have higher treatment costs and lower QoL scores than patients without EPI. The prevalence of EPI as a comorbid condition is high, particularly in patients with cystic fibrosis.
Assuntos
Efeitos Psicossociais da Doença , Análise Custo-Benefício , Insuficiência Pancreática Exócrina , Qualidade de Vida , Humanos , Insuficiência Pancreática Exócrina/economia , Insuficiência Pancreática Exócrina/terapia , Fibrose Cística/terapia , Fibrose Cística/economia , Fibrose Cística/psicologia , Fibrose Cística/complicações , Custos de Cuidados de Saúde/estatística & dados numéricos , PrevalênciaAssuntos
Análise Custo-Benefício , Fibrose Cística , Medicamentos Genéricos , Fibrose Cística/tratamento farmacológico , Fibrose Cística/economia , Humanos , Medicamentos Genéricos/economia , Aminofenóis/economia , Aminofenóis/uso terapêutico , Benzodioxóis/economia , Benzodioxóis/uso terapêutico , Quinolonas/economia , Quinolonas/uso terapêutico , Custos de Medicamentos , Aminopiridinas/economia , Aminopiridinas/uso terapêutico , Combinação de Medicamentos , Análise de Custo-EfetividadeRESUMO
BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) has revolutionized cystic fibrosis (CF) treatment. However, previous research has demonstrated profound global disparities in diagnosis and treatment access. If unaddressed, these threaten to widen existing health inequities. Therefore, in this analysis we aimed to reappraise gaps and evaluate progress in diagnosis and treatment equity in high-income (HIC) versus low- and middle-income countries (LMICs). METHODS: Estimates of the global CF population were made in 158 countries using patient registries, systematic literature searches, and an international survey of 14 CF experts. Estimates of the global burden of undiagnosed CF were made using epidemiological studies identified in literature searches and registry coverage data. The proportion of people receiving ETI was estimated using publicly available revenue data and a survey of 23 national drug pricing databases. RESULTS: 188,336 (163,421-209,204) people are estimated to have CF in 96 countries. Of these, 111,767 (59%) were diagnosed and 51,322 (27%) received ETI. The undiagnosed patient burden is estimated to be 76,569 people, with 82% in LMICs. ETI is reimbursed in 35 HICs, but only one LMIC. Four years after approval, there are 13,723 people diagnosed with CF who live in a country where ETI is inaccessible. This increases to 76,199 when including the estimated undiagnosed population. CONCLUSIONS: Equitable access to CFTR modulators must become a top priority for the international CF community. ETI costs up to $322,000 per year but could be manufactured for $5000 to allow access under a voluntary license. Given the extent of disparities, other mechanisms to improve access that circumvent the manufacturer should also be considered.
Assuntos
Aminofenóis , Fibrose Cística , Saúde Global , Acessibilidade aos Serviços de Saúde , Disparidades em Assistência à Saúde , Quinolonas , Fibrose Cística/diagnóstico , Fibrose Cística/terapia , Fibrose Cística/tratamento farmacológico , Fibrose Cística/economia , Fibrose Cística/epidemiologia , Humanos , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Quinolonas/uso terapêutico , Aminofenóis/uso terapêutico , Aminofenóis/economia , Disparidades em Assistência à Saúde/estatística & dados numéricos , Disparidades em Assistência à Saúde/economia , Benzodioxóis/uso terapêutico , Combinação de Medicamentos , Pirazóis/uso terapêutico , Piridinas/uso terapêutico , Criança , Países em Desenvolvimento , Países Desenvolvidos/estatística & dados numéricos , Indóis , QuinolinasAssuntos
Aminofenóis , Benzodioxóis , Fibrose Cística , Combinação de Medicamentos , Indóis , Pirazóis , Quinolonas , Humanos , Fibrose Cística/tratamento farmacológico , Fibrose Cística/economia , Benzodioxóis/uso terapêutico , Benzodioxóis/farmacocinética , Aminofenóis/uso terapêutico , Aminofenóis/farmacocinética , Aminofenóis/economia , Quinolonas/uso terapêutico , Quinolonas/farmacocinética , Quinolonas/economia , Indóis/economia , Indóis/uso terapêutico , Indóis/farmacocinética , Pirazóis/uso terapêutico , Pirazóis/farmacocinética , Pirazóis/economia , Piridinas/farmacocinética , Piridinas/uso terapêutico , Piridinas/economia , Quinolinas/uso terapêutico , Quinolinas/farmacocinética , Quinolinas/economia , Custos de Medicamentos , Acessibilidade aos Serviços de Saúde/economia , Disparidades em Assistência à Saúde/economia , Agonistas dos Canais de Cloreto/uso terapêutico , Agonistas dos Canais de Cloreto/farmacocinética , Agonistas dos Canais de Cloreto/economia , Pirrolidinas/uso terapêutico , Pirrolidinas/farmacocinéticaRESUMO
BACKGROUND: Better insights into the natural course of cystic fibrosis (CF) have led to treatment approaches that have improved pulmonary health and increased the life expectancy of affected individuals. This study evaluated how the combination of modified demographics and changes in CF management impacted resource consumption and the cost of care. METHODS: Medical records of CF patients from 2006 to 2016 in the French CF Registry were linked to their corresponding claims data (SNDS). Medications, medical visits, procedures, hospitalisations, and indirect costs were annualized by calendar year from 2006 to 2017. RESULTS: Of the 7,671 patients included in the French CF Registry, 6,187 patients (80.7%) were linked to the SNDS (51.9% male, mean age = 24.7 years). The average cost per patient was 14,174 in 2006, 21,920 in 2011 and 44,585 in 2017. Costs associated with hospital stays increased from 3,843 per patient in 2006 to 6,741 in 2017. In 2017, the mean cost per CF patient was allocated as follows: 72% for medications (of which 51% for modulator therapies), 15% for hospital stays, 7% for medical visits, 3% for indirect costs, 2% for medical devices, 1% for outpatient medical procedures. CONCLUSION: There was a strong increase in the mean annual cost per CF patient between 2006 and 2017, mostly due to the cost of therapy after the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The combination of an increase in the number of CF patients - particularly adult patients - and an increase in the annual cost per patient led to a substantial increase in the total cost of CF disease care for the health systems.
Assuntos
Fibrose Cística/economia , Fibrose Cística/terapia , Custos de Cuidados de Saúde/tendências , Adolescente , Adulto , Criança , Pré-Escolar , Estudos Transversais , Feminino , Humanos , Masculino , Aceitação pelo Paciente de Cuidados de Saúde , Adulto JovemRESUMO
BACKGROUND: Home spirometry with regular symptom assessment is one strategy to track lung health to intervene early in episodes of pulmonary exacerbations (PE). In a multi-center randomized controlled trial home spirometry and symptom tracking demonstrated no significant differences regarding the primary clinical endpoint, FEV1, compared to usual care, but did identify differences in healthcare utilization. We used data from the Early Intervention in Cystic Fibrosis Exacerbation (eICE) study to evaluate whether home monitoring of PE is a cost-minimizing intervention in the context of this randomized trial. METHODS: We reviewed healthcare resource utilization of all 267 eICE participants, including outpatient visits, antibiotics and hospitalizations. Prices were identified in the IBM/Watson MarketScanâ Commercial Claims and Encounters Databases and averaged over the 2014-2017 period. Using total healthcare utilization costs, we generated summary statistics by intervention and protocol arm (total cost, mean cost, standard deviation). We performed Welch Two Sample t-tests to determine if total costs and cost by type of utilization differed significantly between groups. RESULTS: Outpatient visit costs were significantly higher by 13% in the Early Intervention (EI) than in the usual care (UC) arm ($3,345 vs. $2,966). We found no significant differences in outpatient antibiotic, hospitalization, or total health care costs between the arms. CONCLUSIONS: Within the context of the eICE trial, outpatient visits were significantly higher in those with experimental home spirometry care, but that did not translate into statistically significant differences of overall health care costs between the two arms.
Assuntos
Fibrose Cística/economia , Fibrose Cística/terapia , Custos de Cuidados de Saúde , Espirometria/economia , Espirometria/métodos , Adolescente , Criança , Feminino , Serviços de Assistência Domiciliar , Humanos , Masculino , Aceitação pelo Paciente de Cuidados de Saúde , Estudos Prospectivos , Estudos RetrospectivosRESUMO
BACKGROUND: Chronic care delivery models faced unprecedented financial pressures, with a reduction of in-person visits and adoption of telehealth during the COVID-19 pandemic. We sought to understand the reported financial impact of pandemic-related changes to the cystic fibrosis (CF) care model. METHODS: The U.S. CF Foundation State of Care surveys fielded in Summer 2020 (SoC1) and Spring 2021 (SoC2) included questions for CF programs on the impact of pandemic-related restrictions on overall finances, staffing, licensure, and reimbursement of telehealth services. Descriptive analyses were conducted based on program type. RESULTS: Among the 286 respondents (128 pediatric, 118 adult, 40 affiliate), the majority (62%) reported a detrimental financial impact to their CF care program in SoC1, though fewer (42%) reported detrimental impacts in SoC2. The most common reported impacts in SoC1 were redeployment of clinical staff (68%), furloughs (52%), hiring freezes (51%), decreases in salaries (34%), or layoffs (10%). Reports of lower reimbursement for telehealth increased from 30% to 40% from SoC1 to SoC2. Projecting towards the future, only a minority (17%) of program directors in SoC2 felt that financial support would remain below pre-pandemic levels. CONCLUSIONS: The COVID-19 pandemic resulted in financial strain on the CF care model, including challenges with reimbursement for telehealth services and reductions in staffing due to institutional changes. Planning for the future of CF care model needs to address these short-term impacts, particularly to ensure a lack of interruption in high-quality multi-disciplinary care.
Assuntos
COVID-19 , Continuidade da Assistência ao Paciente , Fibrose Cística , Acessibilidade aos Serviços de Saúde , Modelos Organizacionais , Telemedicina , Adulto , COVID-19/epidemiologia , COVID-19/prevenção & controle , Criança , Continuidade da Assistência ao Paciente/organização & administração , Continuidade da Assistência ao Paciente/normas , Custos e Análise de Custo , Fibrose Cística/economia , Fibrose Cística/epidemiologia , Fibrose Cística/terapia , Acessibilidade aos Serviços de Saúde/organização & administração , Acessibilidade aos Serviços de Saúde/tendências , Necessidades e Demandas de Serviços de Saúde , Humanos , Inovação Organizacional , Admissão e Escalonamento de Pessoal/organização & administração , Mecanismo de Reembolso/tendências , SARS-CoV-2 , Telemedicina/economia , Telemedicina/métodos , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Due to the COVID-19 pandemic, there was an uptake of telehealth in cystic fibrosis care. Previous studies show disparities in telehealth use based on socioeconomic status (SES). We aimed to: (1) understand telehealth use and perceptions and (2) identify the facilitators and barriers to telehealth use among people with CF and their families (PwCF) from diverse racial/ethnic and socioeconomic backgrounds. METHODS: We conducted an analysis of the 2020 Cystic Fibrosis State of Care surveys completed by PwCF (PFSoC), CF Care Programs (SoC1) and the CF Foundation Patient Registry (CFFPR). RESULTS: A total of 424 PwCF and 286 programs responded to the PFSoC and SoC1. Among PwCF, 90% self-identified as White, 6% as Hispanic/Latino, and 2% as Black. Racial/ethnic minorities were less likely to have had a telehealth visit (p=.015). This difference was pronounced among the Hispanic/Latino population (p<.01). Telehealth use did not differ by health insurance and was similarly offered independent of financial status. Compared to PwCF who denied financial constraints, those who reported financial difficulties found telehealth more difficult to use (p=.018) and were less likely to think that their concerns (p=.010) or issues that mattered most to them (p=.020) were addressed during telehealth. Programs perceived lack of technology, language barriers, and home conditions as barriers to telehealth in vulnerable populations. CONCLUSION: PFSoC and SoC1 identified differences in telehealth use and care perceptions by ethnicity, race, and socioeconomic characteristics. Further studies are needed to understand how telehealth can change access to CF care in diverse subpopulations.
Assuntos
COVID-19 , Barreiras de Comunicação , Fibrose Cística , Saúde das Minorias , Telemedicina , COVID-19/epidemiologia , COVID-19/prevenção & controle , Controle de Doenças Transmissíveis/métodos , Fibrose Cística/economia , Fibrose Cística/etnologia , Fibrose Cística/psicologia , Fibrose Cística/terapia , Estresse Financeiro/etnologia , Acessibilidade aos Serviços de Saúde/organização & administração , Acessibilidade aos Serviços de Saúde/tendências , Disparidades em Assistência à Saúde/etnologia , Disparidades em Assistência à Saúde/normas , Humanos , Saúde das Minorias/etnologia , Saúde das Minorias/normas , Saúde das Minorias/estatística & dados numéricos , Avaliação das Necessidades , Inovação Organizacional , SARS-CoV-2 , Fatores Socioeconômicos , Telemedicina/organização & administração , Telemedicina/normas , Estados Unidos/epidemiologia , Populações Vulneráveis/estatística & dados numéricosRESUMO
DISCLOSURES: No funding contributed to the writing of this commentary. Both authors are employed by the Cystic Fibrosis Foundation. The Cystic Fibrosis Foundation has entered into therapeutic development award agreements and licensing agreements to assist with the development of CFTR modulators that may result in intellectual property rights, royalties, and other forms of consideration provided to CFF. Some of these agreements are subject to confidentiality restrictions and, thus, CFF cannot comment on them.
Assuntos
Agonistas dos Canais de Cloreto/uso terapêutico , Regulador de Condutância Transmembrana em Fibrose Cística/agonistas , Fibrose Cística/tratamento farmacológico , Custos de Medicamentos , Aminofenóis/economia , Aminofenóis/uso terapêutico , Benzodioxóis/economia , Benzodioxóis/uso terapêutico , Agonistas dos Canais de Cloreto/economia , Fibrose Cística/economia , Fibrose Cística/genética , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Aprovação de Drogas/economia , Combinação de Medicamentos , Humanos , Indóis/economia , Indóis/uso terapêutico , Assistência Médica , Mutação , Pirazóis/economia , Pirazóis/uso terapêutico , Piridinas/economia , Piridinas/uso terapêutico , Quinolinas/economia , Quinolinas/uso terapêutico , Quinolonas/economia , Quinolonas/uso terapêutico , Resultado do Tratamento , Estados Unidos , United States Food and Drug AdministrationRESUMO
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Seidner, Rind, and Pearson are employed by ICER. Tice reports contracts to his institution, University of California, San Francisco, from ICER during the conduct of this study. Wherry has nothing to disclose.
Assuntos
Agonistas dos Canais de Cloreto/uso terapêutico , Análise Custo-Benefício , Regulador de Condutância Transmembrana em Fibrose Cística/agonistas , Fibrose Cística/tratamento farmacológico , Modelos Econômicos , Adolescente , Aminofenóis/economia , Aminofenóis/uso terapêutico , Aminopiridinas/economia , Aminopiridinas/uso terapêutico , Benzodioxóis/economia , Benzodioxóis/uso terapêutico , Criança , Agonistas dos Canais de Cloreto/economia , Fibrose Cística/economia , Fibrose Cística/genética , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Aprovação de Drogas/economia , Combinação de Medicamentos , Custos de Medicamentos , Política de Saúde/economia , Humanos , Indóis/economia , Indóis/uso terapêutico , Mutação , Pirazóis/economia , Pirazóis/uso terapêutico , Piridinas/economia , Piridinas/uso terapêutico , Quinolinas/economia , Quinolinas/uso terapêutico , Quinolonas/economia , Quinolonas/uso terapêutico , Resultado do Tratamento , Estados Unidos , United States Food and Drug AdministrationRESUMO
OBJECTIVES: Cystic fibrosis (CF) is a rare genetic disease with no cure. Until recently, treatment has targeted symptoms of the disease and not the disease-causing genetic defect. Ivacaftor is included in a new class of breakthrough drugs targeting the genetic defects of CF. We sought to estimate the long-term cost-effectiveness of ivacaftor from a US payer perspective. METHODS: We developed an individual-level microsimulation model that followed a cohort of heterogeneous US CF patients over a lifetime. The primary outcome of interest was quality-adjusted life years (QALYs). We also compared unadjusted life years, count of acute pulmonary exacerbations, and count of lung transplants over a lifetime between patients treated with ivacaftor plus best supportive care and patients treated with best supportive care alone. We conducted one-way and probabilistic sensitivity analyses to test the impact of various model inputs and uncertainties. RESULTS: We found a substantial increase in QALYs, life years, and treatment costs over a lifetime for patients treated with ivacaftor plus best supportive care versus best supportive care alone. Discounted results for ivacaftor were 22.92 QALYs and $8 797 840 in total lifetime costs compared to 16.12 QALYs and $2 336 366 lifetime costs for best supportive care alone. The incremental cost-effectiveness ratios (ICERs) were $950 217 per QALY. Results from the probabilistic sensitivity analysis indicated a 0% chance that ivacaftor was cost-effective at a willingness-to-pay (WTP) threshold of $500 000 per QALY. CONCLUSIONS: Treatment with ivacaftor plus best supportive care versus best supportive care alone is not cost-effective at or near commonly accepted WTP thresholds.
Assuntos
Aminofenóis/uso terapêutico , Agonistas dos Canais de Cloreto/uso terapêutico , Fibrose Cística/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Quinolonas/uso terapêutico , Aminofenóis/economia , Agonistas dos Canais de Cloreto/economia , Análise Custo-Benefício , Fibrose Cística/tratamento farmacológico , Fibrose Cística/genética , Custos de Medicamentos , Feminino , Humanos , Masculino , Mutação/genética , Anos de Vida Ajustados por Qualidade de Vida , Quinolonas/economia , Fatores de TempoRESUMO
Introduction: Cystic fibrosis is an autosomal recessive genetic disease classified as a highcost orphan disease. Objective: To determine the cost-effectiveness ratio of the diagnostic test for the CFTR gene-sequencing in asymptomatic family carriers in the first, second, and third degree of consanguinity. Materials and methods: We conducted a systematic search evaluating operative characteristics of the diagnostic test and decision-tree models in cost-effectiveness studies. A decision-tree model was elaborated taking prevention of future conceptions as a unit of analysis. We obtained the costs of the disease from the high-cost report of the Ministerio de Salud y Protección Social. The costs of the test were referenced by national laboratories. We carried out a deterministic and probabilistic sensitivity analysis with a third-payer perspective and a one-year horizon. Results: An ICER of USD$ 5051.10 was obtained as the incremental cost for obtaining 10.89% more probability of avoiding the birth of a child with cystic fibrosis per screened couple. For family members in second and third degrees, the ICER was USD$ 19,380.94 and USD$ 55,913.53, respectively, evidenced when applying the GDP per capita. This technology was cost-effective in 39%, 61.18%, and 74.36% for 1, 2, and 3 GDP per capita in first degree of consanguinity relatives. Conclusions: The genetic test for the detection of CFTR gene carriers was cost-effective depending on the threshold of availability to pay and the assumptions and limitations established in the model.
Introducción. La fibrosis quística es una enfermedad genética de carácter autosómico recesivo clasificada como enfermedad huérfana de alto costo. Objetivo. Determinar la razón de costo-efectividad de la prueba diagnóstica de secuenciación del gen CFTR para los portadores asintomáticos familiares en primer, segundo y tercer grados de consanguinidad. Materiales y métodos. Se hizo una búsqueda sistemática sobre la evaluación de las características operativas de la prueba diagnóstica y los modelos de árbol de decisiones en estudios de costo-efectividad. Se elaboró un modelo de árbol de decisiones tomando como unidad de análisis la prevención de futuras concepciones. Los costos de la enfermedad se obtuvieron del reporte de alto costo del Ministerio de Salud de Colombia. Los costos de la prueba se obtuvieron de laboratorios nacionales. Se hizo un análisis de sensibilidad, determinístico y probabilístico, con la perspectiva del tercer pagador y horizonte a un año. Resultados. Se obtuvo una razón incremental de costo-efectividad (RICE) de USD$5.051,10 por obtener 10,89 % más de probabilidades de evitar el nacimiento de un niño enfermo con fibrosis quística por pareja. Para los familiares de segundo y tercer grados, se encontró una RICE de USD$ 19.380,94 y USD$ 55.913,53, respectivamente, al aplicar el PIB per cápita. Esta tecnología fue costo-efectiva en 39 %, 61,18 % y 74,36 % para 1, 2 y 3 PIB per cápita en familiares de primer grado de consanguinidad. Conclusiones. La prueba genética de detección de portadores del gen CFTR resultó costo-efectiva dependiendo del umbral de la disponibilidad de pagar, y de los supuestos y limitaciones establecidas en el modelo.
Assuntos
Regulador de Condutância Transmembrana em Fibrose Cística/genética , Análise Mutacional de DNA/economia , Triagem de Portadores Genéticos/economia , Doenças Assintomáticas , Viés , Colômbia/epidemiologia , Análise Custo-Benefício , Fibrose Cística/economia , Fibrose Cística/epidemiologia , Fibrose Cística/genética , Fibrose Cística/prevenção & controle , Árvores de Decisões , Triagem de Portadores Genéticos/métodos , Aconselhamento Genético , Humanos , Reembolso de Seguro de Saúde , Aceitação pelo Paciente de Cuidados de Saúde , Probabilidade , Sensibilidade e Especificidade , Análise de Sequência de DNA/economiaRESUMO
PURPOSE OF REVIEW: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a highly prevalent disease that results in significant healthcare-related costs as well as costs to society with lost productivity and time. Unfortunately, a significant percentage of patients who suffer with this disease will not find relief from current standard of care medications and surgery. With ongoing efforts to understand the pathophysiology of CRSwNP has come the introduction of monoclonal antibodies, or "biologics," targeting specific elements of the inflammatory pathway in CRSwNP. Despite efficacy, these come at significant cost and, to date, no studies on the cost-efficacy of these biologics in CRSwNP have been published. RECENT FINDINGS: Multiple studies have now demonstrated efficacy for biologics in the treatment of CRSwNP as a primary indication. However, the gains in quality of life and objective measures, while consistent, are small and, arguably, the clinical significance is still unclear. In addition, the high cost of these medications may be hard to justify when evaluated in cost-efficacy studies against standard of care therapy in CRSwNP. Furthermore, while the current literature is most robust in showing the benefit of the biologics in asthma, it does not fully support cost-efficacy for biologics. This review evaluates the current literature regarding efficacy of monoclonal antibodies for the treatment of CRSwNP and considers this efficacy in light of the cost implications to individuals and society.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Produtos Biológicos/uso terapêutico , Pólipos Nasais/tratamento farmacológico , Rinite/tratamento farmacológico , Sinusite/tratamento farmacológico , Anticorpos Monoclonais/economia , Produtos Biológicos/economia , Terapia Biológica/economia , Doença Crônica , Fibrose Cística/tratamento farmacológico , Fibrose Cística/economia , Custos de Cuidados de Saúde , Humanos , Pólipos Nasais/economia , Rinite/economia , Sinusite/economia , Resultado do TratamentoRESUMO
Importance: Sickle cell disease (SCD) and cystic fibrosis (CF) are severe autosomal recessive disorders associated with intermittent disease exacerbations that require hospitalizations, progressive chronic organ injury, and substantial premature mortality. Research funding is a limited resource and may contribute to health care disparities, especially for rare diseases that disproportionally affect economically disadvantaged groups. Objective: To compare disease-specific funding between SCD and CF and the association between funding and research productivity. Design, Setting, and Participants: This cross-sectional study examined federal and foundation funding, publications indexed in PubMed, clinical trials registered in ClinicalTrials.gov, and new drug approvals from January 1, 2008, to December 31, 2018, in an estimated US population of approximately 90â¯000 individuals with SCD and approximately 30â¯000 individuals with CF. Main Outcomes and Measures: Federal and foundation funding, publications indexed in PubMed, clinical trial registrations, and new drug approvals. Results: From 2008 through 2018, federal funding was greater per person with CF compared with SCD (mean [SD], $2807 [$175] vs $812 [$147]; P < .001). Foundation expenditures were greater for CF than for SCD (mean [SD], $7690 [$3974] vs $102 [$13.7]; P < .001). Significantly more research articles (mean [SD], 1594 [225] vs 926 [157]; P < .001) and US Food and Drug Administration drug approvals (4 vs 1) were found for CF compared with SCD, but the total number of clinical trials was similar (mean [SD], 27.3 [6.9] vs 23.8 [6.3]; P = .22). Conclusions and Relevance: The findings show that disparities in funding between SCD and CF may be associated with decreased research productivity and novel drug development for SCD. Increased federal and foundation funding is needed for SCD and other diseases that disproportionately affect economically disadvantaged groups to address health care disparities.
Assuntos
Anemia Falciforme/economia , Pesquisa Biomédica , Fibrose Cística/economia , Apoio à Pesquisa como Assunto , Anemia Falciforme/epidemiologia , Pesquisa Biomédica/economia , Pesquisa Biomédica/estatística & dados numéricos , Estudos Transversais , Fibrose Cística/epidemiologia , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/estatística & dados numéricos , Fundações , Humanos , Apoio à Pesquisa como Assunto/economia , Apoio à Pesquisa como Assunto/organização & administração , Estados UnidosRESUMO
BACKGROUND: Lumacaftor-ivacaftor combination is a promising treatment for cystic fibrosis (CF) patients homozygous for the F508del-CFTR mutation. Optimal adherence is essential to achieve full health outcomes benefits. METHODS: This retrospective study used pharmacy refills data to calculate proportion of days covered (PDC). Adherence was defined as a PDC ≥80%. A logistic regression analysis was conducted to examine factors associated with medication adherence. RESULTS: Ninety-six patients were included in the final cohort for analysis. The mean PDC was 96% ± 14 at 6 months, and 91% ± 17 at 12 months. The proportion of adherent patients was 89% and 83% at 6 and 12 months respectively. Age and ppFEV1 were found to affect medication adherence. CONCLUSIONS: Considering the medico-economic impact of CFTR modulator therapy, high adherence rates to lumacaftor-ivacaftor found in this study are encouraging.